Literature DB >> 8966367

Severe community-acquired pneumonia: a possible role for Chlamydia pneumoniae.

R Cosentini1, F Blasi, R Raccanelli, S Rossi, C Arosio, P Tarsia, A Randazzo, L Allegra.   

Abstract

Between July 1992 and June 1993, 61 patients with severe community-acquired pneumonia were admitted to our semi-intensive care unit. For all patients chest X-ray, blood gas analysis while breathing room air, Gram stain and culture of bronchoaspirate, determination of acute and convalescent anti-body titers for Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae, blood culture when body temperature was greater than 38 degrees C, and pharyngeal swab for C. pneumoniae detection by means of an indirect immunofluorescence test were obtained. Among the patients enrolled, 15 suffered from chronic obstructive pulmonary disease, 18 had serious chronic diseases, 9 were immunodeficient and 15 had cardiovascular diseases, and only 4 had no underlying disease. Etiologic diagnosis was reached in 30 cases (49%). As expected, due to the high rate of seriously ill patients, gram-negative pathogens were identified most commonly (15%), followed by Streptococcus pneumoniae (10%) and, surprisingly, by C. pneumoniae (10%). These data, showing the possible emergence of Pseudomonas aeruginosa and C. pneumoniae, warrant further studies in order to verify whether the epidemiological pattern of severe community-acquired pneumonia is actually changing.

Entities:  

Mesh:

Year:  1996        PMID: 8966367     DOI: 10.1159/000196519

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  7 in total

1.  Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles.

Authors:  I Puljiz; I Kuzman; O Dakovic-Rode; N Schönwald; B Mise
Journal:  Epidemiol Infect       Date:  2005-11-29       Impact factor: 2.451

Review 2.  The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis.

Authors:  M H Rozenbaum; P Pechlivanoglou; T S van der Werf; J R Lo-Ten-Foe; M J Postma; E Hak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-14       Impact factor: 3.267

3.  Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study.

Authors:  Jang Wook Sohn; Seung Chul Park; Young-Hwa Choi; Heung Jeong Woo; Yong Kyun Cho; Jin Soo Lee; Hee-Sun Sim; Min Ja Kim
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

4.  Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections.

Authors:  R P Verkooyen; D Willemse; S C Hiep-van Casteren; S A Joulandan; R J Snijder; J M van den Bosch; H P van Helden; M F Peeters; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

5.  Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.

Authors:  Adoración Navarro-Torné; Eva Agostina Montuori; Vasiliki Kossyvaki; Cristina Méndez
Journal:  Hum Vaccin Immunother       Date:  2021-06-09       Impact factor: 4.526

6.  Role of Atypical Pathogens and the Antibiotic Prescription Pattern in Acute Bronchitis: A Multicenter Study in Korea.

Authors:  Sunghoon Park; Kil Chan Oh; Ki-Seong Kim; Kyu-Tae Song; Kwang Ha Yoo; Yun Su Shim; Young Ju Lee; Myung Goo Lee; Jang Uk Yun; Hyun Su Kim; Yee Hyung Kim; Won Jun Lee; Do Il Kim; Hyung Gun Cha; Jae-Myung Lee; Jung San Seo; Ki-Suck Jung
Journal:  J Korean Med Sci       Date:  2015-09-12       Impact factor: 2.153

7.  Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns.

Authors:  Wen-Chien Ko; David L Paterson; Anthanasia J Sagnimeni; Dennis S Hansen; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Joseph G McCormack; Victor L Yu
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.